2型糖尿病和前驱糖尿病患者使用移动健康应用程序与体重减轻和血糖控制之间卡塔尔世界杯8强波胆分析的关系(D’lite研究):前瞻性队列研究%A Lim, sulin %A Tay,Melissa Hui Juan %A Ong,Kai Wen %A Johal,Jolyn %A Yap,Qai Ven %A Chan,Yiong Huak %A Yeo,Genevieve Kai Ning %A Khoo,Chin孟%A Yaxley,Alison %+新加坡国立大学医院营养科，5下肯特岭路，119074，新加坡，65 67724580，su_lin_lim@nuhs.edu.sg %K参与%K糖尿病%K前体糖尿病%K移动健康%K mHealth %K移动应用程序%K减肥%K血糖控制%K糖化血红蛋白%K糖化血红蛋白变化%K手机%D 2022 %7 30.9.2022 %9原始论文%J JMIR糖尿病%G英文%X背景:移动健康应用程序越来越多地用作早期干预，以支持糖尿病预防和控制的行为改变，其首要目标是降低整体疾病负担。目的:这项在新加坡进行的前瞻性队列研究，旨在通过技术授权随机对照试验，研究糖尿病生活方式干预干预部门的糖尿病和前驱糖尿病成年人的应用程序参与特征及其与减肥和改善血糖控制的关系。方法:纳入糖尿病和前体糖尿病患者(N=171)，中位年龄为52岁，BMI为29.3 kg/m2，糖化血红蛋白(HbA1c)水平为6.5%，并分配营养师Buddy糖尿病应用程序。在基线、3个月和6个月测量体重和糖化血红蛋白。通过后端仪表板和开发者报告，我们总共追踪了476,300个每日应用粘性数据点。应用粘性数据采用四分位数和周均值(以每周天数表示)进行分析。采用线性混合模型分析确定应用程序使用与百分比体重和HbA1c变化之间的相关性。结果:在6个月时，整体应用粘性的中位数保持在90%以上。 Participants who were actively engaged in ≥5 app features were associated with the greatest overall weight reduction of 10.6% from baseline (mean difference −6, 95% CI −8.9 to −3.2; P<.001) at 6 months. Adhering to the carbohydrate limit of >5.9 days per week and choosing healthier food options for >4.3 days per week had the most impact, eliciting weight loss of 9.1% (mean difference −5.2, 95% CI −8.2 to −2.2; P=.001) and 8.8% (mean difference −4.2, 95% CI −7.1 to −1.3; P=.005), respectively. Among the participants with diabetes, those who had a complete meal log for >5.1 days per week or kept within their carbohydrate limit for >5.9 days per week each achieved greater HbA1c reductions of 1.2% (SD 1.3%; SD 1.5%), as compared with 0.2% (SD 1%; SD 0.6%). in the reference groups who used the features <1.1 or ≤2.5 days per week, respectively. Conclusions: Higher app engagement led to greater weight loss and HbA1c reduction among adults with overweight or obesity with type 2 diabetes or prediabetes. Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12617001112358; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617001112358 %M 36178718 %R 10.2196/35039 %U https://diabetes.www.mybigtv.com/2022/3/e35039 %U https://doi.org/10.2196/35039 %U http://www.ncbi.nlm.nih.gov/pubmed/36178718